Anatara Lifesciences (ASX:ANR) said recruitment for the second stage of its GaRP product trial for irritable bowel syndrome is progressing with around 40 participants enrolled, according to a Thursday filing with the Australian Securities Exchange.
The target participant number for the trial is 60 to 100, the filing said.
The company added two sites in South Australia and Queensland to broaden participation, aiming to complete recruitment in the fourth quarter, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.